Share this article
Share this article
ROCKVILLE, Md., Dec. 14, 2020 /PRNewswire/ Emmes today announced that it has conducted the data and statistical analysis for the second iteration of the Adaptive COVID-19 Treatment Trial (ACTT-2). The ACTT-2 trial assessed the efficacy and safety of a 4-mg dose of baricitinib with remdesivir, versus remdesivir alone, in hospitalized COVID-19 patients.
Baricitinib, produced by Eli Lilly and Company, has been used to treat adults with moderate to severe rheumatoid arthritis. Baricitinib, in combination with remdesivir for COVID-19 patients, received Emergency Use Authorization on November 19.
The ACTT-2 study, which was conducted from May to July 2020, was a randomized, double-blind, placebo-controlled trial that enrolled more than 1,000 participants at more than 60 U.S. and international sites. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, sponsored the trial.